PaxVax Acquires the FDA-Approved Typhoid Vaccine Vivotif

Deal Also Includes Manufacturing and Development Facility in Switzerland

REDWOOD CITY, Calif. -- July 28, 2014 – PaxVax, Inc., a specialty vaccine company focused on travel and biodefense, today announced that it has acquired the oral typhoid vaccine Vivotif® from Crucell Switzerland AG, as well as its manufacturing facility in Thörishaus, near Bern, Switzerland. Additionally, PaxVax is acquiring marketing, sales and distribution capabilities in select markets including the United States, and certain other assets related to travel vaccines such as hepatitis A. Financial terms of the transaction were not disclosed.


Cholera: Haiti 

  • 2010-12 - First outbreak in more than a century
  • More than 580,000+ sickened / 7,500+ dead

Anthrax: New York City

  • Sept. 2001 - FBI stated worst biological attack in U.S. history
  • 5 deaths / 17 sickened

H5N1: Indonesia

  • More than half of H5N1 worldwide deaths occur in Indonesia
  • 60% of Bird Flu (H5N1) cases since 2003 have resulted in death

HIV: Swaziland

  • 230,000 living with HIV in Swaziland, 26% of adults have HIV
  • Worldwide: 60M+ infected / 30M dead

Dengue: Rio de Janeiro

  • Rio de Janeiro reports a dengue epidemic: 50,000+ cases in the city
  • Leading cause of fever among travelers & tourists 

to Better the World

Innovative. Beneficial. Simple.

Our mission is to develop and commercialize innovative vaccines against infectious diseases in a socially responsible manner.

PaxVax: Better Vaccines to Better the World

Subscribe to PaxVax - Socially Responsible Vaccines RSS